Press Releases Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Delayed Nasdaq Other stock markets 12:56:37 10/05/2024 am IST			5-day change	1st Jan Change
1.71 ^USD	+6.54%		+7.55%	-0.71%

01/05	Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects	CI
28/03	Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza	01/05	AQ
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs	28/03	AQ
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A	19/03	AQ
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates	04/01	AQ
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A	06/12	AQ
Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	29/11	AQ
Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023	27/11	AQ
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	13/11	AQ
Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast	09/11	AQ
Cocrystal Pharma : Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 - Form 8-K	31/23/31	PU
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344	31/23/31	AQ
Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus	28/23/28	AQ
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference	05/23/05	AQ
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	14/23/14	AQ
Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead	08/23/08	AQ
Cocrystal Pharma : Investor Presentation	24/23/24	PU
Cocrystal Pharma : Market Offering Agreement - Form 8-K	16/23/16	PU
Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988	31/23/31	AQ
Cocrystal Pharma : Investor Presentation	17/23/17	PU
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs	15/23/15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cocrystal Pharma, Inc.

Equities

COCP

US19188J4094

Press Releases

Filters